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1. Introduction 
Hypertension is one of the most common chronic illnesses effecting more than 1 billion 
people worldwide and is a major risk factor for coronary artery disease and myocardial 
infarction, heart failure, stroke and renal failure. By the year 2025, the global prevalence of 
hypertension is projected to increase to 29.2% in adult population (Kearney et al., 2005). It is 
well established that reduction in blood pressure is associated with decreased 
cardiovascular morbidity and mortality (Lewington, Clarke, Qizilbash, Peto, & Collins, 
2002). Despite the availability of several antihypertensive drugs which include thiazide 
diuretics, beta blockers, Angiotensin-Converting Enzyme (ACE) inhibitors, angiotensin 
receptor blockers (ARB) and calcium channel blockers, global estimates suggest that less 
than 35% of hypertensives are able to achieve their target systolic and diastolic blood 
pressure with these drugs (Thoenes et al., 2009). The current strategy of trial and error 
approach to the management of hypertension is suboptimal and alternative approaches for 
identifying the optimal antihypertensive regimen in a specific patient are needed. One 
potential approach for individualizing antihypertensive therapy is through the use of 
genetic information, or pharmacogenomics, to identify the most appropriate therapy for 
individual patients. Given the health burden associated with hypertension and the poor 
rates of BP control, hypertension pharmacogenomics holds great potential. 
Pharmacogenetics is the science that determines the efficiency and side effects of a medicine 
based on the genetic make-up of an individual (personalized medicine). Potential benefits of 
personalized medicines include prescription of drugs based on a patient's genetic profile 
versus trial and error, hence decreasing the likelihood of adverse reactions and maximizing 
effectiveness (Centre for Genetics Education, 2007). In the current review, we review genetic 
association of blood pressure lowering response to different drug classes of antihypertensive 
therapy in different ethnic populations. 
2. Meta-analysis for pharmacogenetics of hypertension 
In order to compile the current knowledge of pharmacogenetics of anti-hypertensive drugs, 
we searched PubMed using the MESH terms "Pharmacogenetics+hypertension, Genes + 
Hypertension, Blood pressure response + hypertension" in Pubmed limiting results to 
publications on studies in human adults. Similar searches were performed with names of 
specific antihypertensive drugs including Diuretics, Beta-blockers, ARB and ACE inhibitors. 
We further identified specific polymorphisms of genes of interest noted in earlier reviews 
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and performed additional PubMed searches based on these candidate genes. Studies on 
both healthy subjects and patients were included, and there was no time limit on duration of 
drug administration. Studies with both single and multiple drugs were included. Even if our 
information of interest was a small part of the study, it was included. Studies that only 
addressed the association of genetic variants/polymorphisms with hypertension and 
hypertension-induced end-organ damage but not with blood pressure alterations in 
response to anti-hypertensive drugs were not included. Reports related to experimental 
animals, or studies that used manipulated blood pressure (e.g. the attenuation of agonist-
induced blood pressure increase) or were in languages other than English, or in which no 
specific drugs or drug classes were used (i.e. reports on therapy-resistant hypertension in 
general) were not included. Our aim was to collate the existing body of knowledge on 
common genetic polymorphisms and their relationship to blood pressure lowering 
response. We tried to remove bias in the selection of research articles by selecting maximum 
number of studies and from different ethnic groups. A summary of these findings is shown 
in the Table (1). 
2.1 Diuretics 
Diuretics are the first-line treatment of hypertension and Thiazides are most commonly 
prescribed diuretics. Thiazides inhibit Na+/Cl− cotransporter (NCC) in the renal distal 
convoluted tubule, resulting in decreased sodium re-absorption and increased sodium 
excretion, which leads to decreased extracellular fluid (ECF) and plasma volume. This 
volume loss results in diminished venous return, increased renin release, reduced cardiac 
output and decreased blood pressure (CONWAY & LAUWERS, 1960). Varied Blood 
pressure (BP) response to diuretics is observed in hypertensive patients. It has been 
proposed that genetic polymorphisms in several candidate genes such as the Angiotensin-
Converting Enzyme (ACE), alpha-adducin (ADD1), G protein b3-subunit (GNB3) gene, 
angiotensinogen (AGT), angiotensin II receptor1 (AGTR1), etc.  may influence blood 
pressure (BP) response to diuretic therapy (Arnett, Claas, & Glasser, 2006; Gerhard et al., 
2008; C.-C. Huang et al., 2011; Luo, Y. Wang, et al., 2009; Sciarrone et al., 2003; Turner, 
Schwartz, Chapman, & Boerwinkle, 2001; D. Werner et al., 2008). ACE insertion/deletion 
(ACE I/D) polymorphism has been extensively studied for association with blood pressure 
lowering response to diuretics (Bozec et al., 2003; Nordestgaard et al., 2010; Scharplatz, 
Puhan, Steurer, & Bachmann, 2004; Su et al., 2007; Ueda, Meredith, Morton, Connell, & 
Elliott, 1998; Yu, Zhang, & G. Liu, 2003; Zhou, Wu, J.-Q. Liu, Liang, & G.-F. Liu, 2007); 
however conflicting results have been reported in different studies. Both, association / lack 
of association of ACE genotypes with blood pressure-lowering response to diuretics have 
been reported in different studies (Table). For example, a lack of association between ACE 
genotypes and adjusted mean difference in diastolic and systolic blood pressure in 
hypertensive patients on diuretics has been reported in Finnish (Suonsyrjä et al, 2009) and 
Swedish subjects (Schelleman et al 2006); whereas D allele was found to be associated with 
greater systolic blood pressure reduction in hypertensive Chinese patients on 
hydrochlorothiazide (HCTZ)(Jiang et al., 2007; Zhou et al., 2007). Sciarrone et al, 2003, on the 
other hand, showed that I allele of ACE (I/D) polymorphism was significantly associated 
with the largest mean blood pressure (MBP) decrease with HCTZ treatment. It has also been 
observed that response to thiazides may be gender specific (Frazier, S T Turner, G L 
Schwartz, A B Chapman, & E Boerwinkle, 0000; Zhou, Wu, J.-Q. Liu, Liang, & G.-F. Liu, 
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2007); for example, Schwartz et al (2002), reported that ACE II homozygosity in women and 
DD homozygosity in men was associated with the greatest BP lowering responses to HCTZ.   
Two other genes, ADD1 and GNB3 genes have also been shown to influence the response to 
diuretics. ǂ-Adducin is a ubiquitously expressed heterodimeric cytoskeleton protein that 
modulates a variety of cellular functions, including sodium transport. A genetic variant in 
ADD1, namely, Gly460Trp polymorphism has been shown to be associated with renal 
sodium reabsorption, salt-sensitive hypertension and response to diuretic therapy (Glorioso 
et al., 1999). However, the evidence remains inconsistent between studies and across 
populations. There are studies showing that use of diuretics in carriers of the 460Trp allele, 
significantly reduced the risk of cardiovascular outcomes and stroke when compared with 
other antihypertensive treatments (Cusi et al., 1997); however, negative studies, showing no 
significant association of ADD1 gene variants with diuretic mediated reduction in adverse 
cardiovascular events and stroke have also been published (Stephen T Turner, Arlene B 
Chapman, Gary L Schwartz, & Eric Boerwinkle, 2003). Genetics of Hypertension-Associated 
Treatment Study (GenHAT) also did not find Gly460Trp polymorphism to be an important 
modifier of cardiovascular risk. However, female carriers of variant allele treated with 
diuretics showed an increased risk of CHD, suggesting an interaction between gene variant 
and gender (Turner et al., 2008). ADD1 Gly460Trp polymorphism has also not been found to 
influence response to HCTZ in Finnish subjects (Suonsyrjä et al. 2009). A similar study on 
5,979 hypertensive patients in USA showed a greater but non-significant association 
between Gly460Trp polymorphism and BP lowering effect of diuretics (Gerhard et al., 2008). 
GNB3 gene, which encodes Beta subunit of Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) which is associated with signal transduction across cell membranes, has 
been found to influence BP lowering response in hypertensive patients on diuretics; 
homozygous carriers of, GNB3 825TT (rs5443) genotype were found to show greater decline 
in blood pressure than homozygous CC patients in both white Caucasians (190) and African 
Americans (197) (Turner, Schwartz, Chapman, & Boerwinkle, 2001). In ALLHAT 
(Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial), a 
multicenter clinical trial conducted in the United States and Canada, minor C allele carriers 
of natriuretic peptide A gene (NPPA), a gene implicated in the control of extracellular fluid 
volume and electrolyte homeostasis, were found to respond significantly better to the 
diuretic chlorthalidone than carriers of other genotypes (Lynch et al., 2008). A recent study 
has reported that polymorphism in Renin gene may also modulate blood pressure lowering 
response of thiazide diuretics. In this study, it was seen that Renin CC genotype 
(rs11240688), Log PRA and baseline Systolic Bloof Pressure (SBP), all contributed to the BP 
lowering response to Thiazide diuretics in non-diabetic hypertensive Taiwanese patients 
(Huang et al., 2011).  
Several other candidate genes have been also examined for their association with BP 
lowering response to diuretics. For example, Werner et al., in 2008 have shown that 
CYP2C9*3 and SLCO1B1 c.521TC genotypes and female gender were significant and 
independent predictors of the pharmacokinetics of torasemide, a diuretic frequently used in 
treatment of hypertension in a small set of patients. Organic anion transporter (OAT) 1 and 
OAT3, encoded by a tightly linked gene pair, plays a key role in renal secretion of diuretics 
(Nozaki et al., 2007). An intergenic polymorphism between OAT1 and OAT3, rs10792367, 
has been investigated for BP response to the diuretic HCTZ. In a study on 1,106 Chinese 
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patients, no significant association was found even though it appeared to explain the inter 
individual variation in response to HCTZ (Han et al., 2011). The NEDD4L gene encodes E3 
ubiquitin-protein ligase NEDD4-like enzyme, which reduces renal tubular expression of 
epithelial Na+ channel (ENaC) and is influenced by a functional rs4149601 G→A NEDD4L 
polymorphism. As diuretics inhibit renal sodium reabsorption, this polymorphism was 
studied for an effect on the diuretic efficacy. In Nordic Diltiazem Study (NORDIL) Sweden, 
the functional NEDD4L rs4149601 polymorphism was found to significantly influence the 
efficacy of diuretic-based antihypertensive treatment in hypertensive patients (Svensson-
Färbom et al., 2011). Similar results have been reported in Chinese patients, where it was 
found that NEDD4L A-allele carriers showed greater blood pressure reduction than GG 
carriers with HCTZ (Luo et al., 2009). In yet another study, -344 C/T polymorphism in the 
CYP11b2 gene, which encodes aldosterone synthase was evaluated for BP response to 
diuretics in 340 individuals in Brazil; however no significant association between BP 
response and the polymorphism was observed (Lacchini et al., 2009). A genome wide 
association study (GWAS) to identify novel SNPs associated with the anti-hypertensive 
response to the diuretic, hydrochlorothiazide, has shown polymorphisms in two genes, LYZ 
(rs317689) and YEATS4 (rs315135) to be associated with Diastolic blood pressure lowering 
response in independent data set of African Americans and Caucasian white subjects 
(Turner et al., 2008).  
Thus, till date, available literature remains inconclusive regarding predictive effect of 
genotypes on diuretic mediated antihypertensive response, however, with better study 
designs in future and replication of existing associations, it may be feasible to tailor diuretic 
therapy based on a patients’ specific genetic make up. 
2.2 β-blockers 
ǃ-Blockers are competitive antagonists of the ǃ-adrenergic receptors, thereby modulating 
activities in this pathway (Reiter, 2004). Although ǃ blockers are among the most widely 
prescribed of all drug classes for hypertension and various other cardiovascular diseases, ǃ 
blocker therapy often produces variable responses among patients (Lindholm, Carlberg, & 
Samuelsson, 2005; Materson et al., 1993). Polymorphisms in various genes involved in 
sympathetic and renin-angiotensin-aldosterone systems (RAAS) have been investigated for 
association with variability in blood pressure lowering response to ǃ-Blockers. Existing data 
suggests that polymorphisms in ǃ1-adrenoceptor gene (ADRB1), namely, Ser49Gly and 
Arg389Gly may influence blood pressure responses to ǃ-blocker therapy (J. Liu et al., 2006; 
Aquilante et al., 2008). Homozygosity for ADRB1 Arg389 allele has been shown to be 
associated with greater decrease in SBP and DBP changes in Caucasians and Chinese 
hypertensive subjects and ADRB1 Ser49Arg389/Ser49Arg389 haplotype was found to be a 
predictor of a good SBP response to metoprolol, suggesting its predictability across races 
(Aquilante et al., 2008; J. Liu et al., 2006). In healthy volunteers with exercise induced heart 
rate increase, Arg389Arg genotype carriers were also found to show significantly greater 
reduction in systolic blood pressure than Gly389Gly carriers after 1 day of metoprolol 
treatment; however, plasma metoprolol concentrations were not significantly different 
between Arg389Arg and Gly389Gly genotypes 3 hours after metoprolol treatment, 
suggesting that differences in response were not due to variability in metoprolol 
pharmacokinetics (J Liu et al., 2003). However, no significant genotype based effects of 
www.intechopen.com
 
Pharmacogenetics of Essential Hypertension 
 
199 
ADRB1 Ser49 and Arg389 polymorphism have been observed with dobutamine (Aquilante 
et al., 2008) or fluoxetine and paoxetine in Caucasian Americans (Turner et al., 2008). ADRB1 
Ser49Gly and Arg389Gly and ADRB2 Cys19Arg, Gly16Arg and Gln27Glu polymorphisms 
were also not found to significantly affect BP response to Atenolol (Filigheddu et al., 2010). 
In contrast, Pacanowski et al. (2008) found Ser49Gly and Arg389Gly to be significantly 
associated with response to atenolol in a study of 5,979 patients from 184 sites in the United 
States and Puerto Rico. 
Three SNPs in the GNB3 gene, A3882C, G5249A and C825T have been found to have a 
significant effect on blood pressure response to atenolol in the female participants in 
Caucasian Americans (Filigheddu et al., 2010). Carvedilol is a non-selective ǂ and ǃ blocker 
that reduces the BP by blocking the binding of Norepinephrine to ǃ1- and ǃ2-adrenergic 
receptors (Stafylas & Sarafidis, 2008). Although polymorphism in CYP2D6 impact 
pharmacokinetics and pharmacodynamics of carvedilol, it has been shown to have no effect 
on the blood pressure response to the drug (Sehrt et al. 2011). However, ADRB2 Gln27 
carriers were recently reported to show greater reduction in resting BP with carvedilol 
compared with Glu27carriers in Russian subjects (Tepliakov et al., 2010).  
The Glu41Leu polymorphism in GRK5 enhances desensitization of the ǃ1-adrenergic 
receptor and has been postulated to confer endogenous ‘genetic ǃ-blockade’ and contribute 
to an attenuated response to ǃ-blockers in black subjects. Thus GRK5 Gln41Leu variant 
could contribute to ethnicity base inter-individual variability in response to ǃ-blockade 
between black and Caucasian individuals (Liggett et al., 2008). Kurnik et al. (2009), however, 
have observed that GRK5 Gln41Leu polymorphism did not contribute to the ethnic 
differences in sensitivity to atenolol among Black and Caucasian individuals.  
NEDD4L polymorphism has been found to influence renal tubular expression of epithelial 
Na+ channel (EnaC) (Luo et al., 2009). Gene variants of Gsǂ (FokI polymorphism), and 
NEDD4L (rs4149601, G→A) polymorphisms have been investigated for a role in the blood 
pressure response to ǃ blockers. Gsǂ genotype was not found to be a significant 
independent predictor of BP response (Jia et al., 1999); whereas NEDD4L rs4149601 
polymorphism was shown to influence the efficacy of ǃ-blockers in the NORDIL study 
(Svensson-Färbom et al., 2011).  
Most of the existing data on pharmacogenetics of ǃ- blockers remains inconclusive and 
further studies are needed to correlate the genotype -drug response to ǃ- blockers in large 
populations from different ethnic communities so as to be an effective predictive tool. 
2.3 ACE inhibitors 
ACE inhibitors are one of the most commonly prescribed antihypertensives and block the 
production of angiotensin II by inhibiting ACE (encoded by the ACE gene), an enzyme that 
converts Angiotensin I to Angiotensin II (Cody, 1997). Polymorphisms in RAAS genes have 
been shown to influence antihypertensive response of ACE inhibitors, but the results have 
been contradictory and inconclusive (Lillvis & Lanfear, 2010). The commonly studied 
variations have been I/D polymorphism in the ACE gene, AGT Met235Thr polymorphism in 
the AGT gene and AGTR1- A1166C polymorphism (rs5186) (Rosskopf & Michel, 2008; 
Scharplatz, Puhan, Steurer, & Bachmann, 2004). Both, D and I alleles of ACE I/D 
Polymorphism were shown to be associated with BP lowering response to ACE Inhibitors in 
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hypertensives in earlier studies (Ueda et al, 1998, Kurland et al, 2001); however, recent studies 
in larger cohorts have failed to replicate the BP response modulation by ACE inhibitors (Yu, 
Zhang, & Liu, 2003, D. K Arnett et al., 2005, F. Filigheddu et al., 2008). Recently, another ACE 
SNP, rs4343, which is located near the ACE I/D and is in linkage disequilibrium with it, has 
been reported to be strongly associated with BP response to ACE inhibitors in a Genome Wide 
Association Study (C-M Chung et al., 2010). However this association could not be reproduced 
in the large randomized placebo controlled EUROPA trial (Brugts et al., 2010).  
Besides ACE gene variants, 235T allele of AGT (M235T) gene has also been found to be 
associated with BP response to ACE inhibitors in several studies (Table). However, a recent 
study with larger sample size did not show any significant association of this variant with 
BP response to ǃ blockers (Schelleman et al., 2007). Su et al., 2007 have reported the 
association of other AGT SNPs with BP response to benazepril, an ACE Inhibitor. These 
authors also found a significant association of AGT gene polymorphisms, C11537A (rs7079), 
rs2638362 (C/T) and rs2640543 (G/A) with BP response to ACE inhibitors (Su et al., 2007). 
AGTR1, which is an important receptor in the RAAS system and plays a crucial role in BP 
control (Atlas, 2007), is an important candidate for study of genetic variation-
pharmacological associations. Its genetic variant, A1166C has been extensively evaluated for 
an effect on BP lowering by ACE inhibitors (Redon, Luque-Otero, Martell, & Chaves, 2004; 
Scharplatz et al., 2004) but recent studies have not found any significant effect of this variant 
with BP lowering ability of ACE inhibitors (Brunner et al., 2007; Filigheddu et al., 2008; 
Konoshita, 2011; Nordestgaard et al., 2010; Redon, Luque-Otero, Martell, & Chaves, 2004; H. 
Yu et al., 2009). Besides these commonly studied polymorphisms, the bradykinin B1 
receptor gene (BDKRB1) SNP (rs12050217) and the ABO gene polymorphisms (rs495828 and 
rs8176746) have been also found to be significantly associated with blood pressure response 
to ACE inhibitors (Brugts et al., 2010; Chung et al., 2010). 
2.4 Angiotensin Receptor Blockers (ARB) 
Angiotensin receptor blockers (ARBs), also known as sartans, block the activation of 
angiotensin type 1 receptors and have a recognized role in the treatment of blood pressure. 
Studies on ARB pharmacogenetics have commonly focused on genes of RAAS system. A 
small-scale study investigated the role of AGTR1- A1166C polymorphism in patients with 
heart failure who were taking ARB (candesartan) in addition to the ACE inhibitor for BP 
control. This study observed that AGTR1 A1166C polymorphism significantly influenced the 
BP response to candesartan (de Denus et al., 2008). However, studies on larger cohorts could 
not replicate association of AGTR1 A1166C and C573T polymorphisms on the efficacy of ARBs 
(Konoshita, 2011; Nordestgaard et al., 2010). Variants of other RAAS genes such as ACE (I/D), 
AGT (M235T) and AT2 variants have not been found to be significantly associated with the 
action of ARB in BP lowering (Konoshita, 2011; Nordestgaard et al., 2010). A recent study has 
reported that C-5312T polymorphism of the renin gene (REN) was associated with 
pharmacogenetics of ARBs (Konoshita, 2011). Additionally, some pilot studies have been 
conducted on small sample sizes (n=31 to 49) that show significant associations but they need 
to be reproduced in larger cohorts. In one of these small-scale study, for example, Cytochrome 
P450 CYP2C9 enzyme (CYP2C9) that metabolizes angiotensin II type 1 (AT (1)) receptor 
antagonists losartan and irbesartan, has been found to be associated with the DBP response to 
irbesartan (Hallberg et al., 2002). In another study, AGTR1 5245 TT genotype was found to be 
associated with plasma concentrations of irbesartan, a specific angiotensin II type 1 receptor 
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(AGTR1) antagonist and the blood pressure response in hypertensive patients (Kurland et al., 
2008). However, these results can't be considered reliable on account of the small sample sizes 
and need to be validated with larger sample sizes. 
2.5 Calcium channel blockers 
The large-conductance calcium and voltage-dependent potassium (BK) channel found in 
vascular smooth muscle is comprised of pore-forming-ǂ and regulatory-ǃ1 subunits 
(Fernández-Fernández et al., 2004). The BK channel, particularly the ǃ1 subunit, functions in 
a negative feedback mechanism to enhance calcium sensitivity, decrease cell excitability, 
and limit smooth muscle contraction (Fernández-Fernández et al., 2004). Calcium channels 
are present in the smooth muscles that line the blood vessels. By relaxing these smooth 
muscles, calcium channel blockers dilate the blood vessels and reduce the BP (Jun et al., 
2010). Calcium channel blockers are commonly used in the treatment of hypertension and 
angina but the response is widely variable (Nguyen, Parker, Noujedehi, Sullivan, & J A 
Johnson, 2000). This variability may be best explained by genetic variation and identifying 
the exact cause of this varied response to calcium channel blockers is important in 
personalizing treatment for hypertension. The gene that encodes the ǃ1 subunit of the BK 
channel is KCNMB1, which is likely to carry polymorphisms, which affect the efficacy of 
calcium channel blockers. Glu65Lys and Val110Leu are the two commonly studied 
polymorphisms in this gene (Brunner et al., 2007; Plüger et al., 2000). In the INVEST-GENE 
study, BP response to Verapamil SR was not found to differ by KCNMB1 genotypes. 
However, individuals with Lys65 allele were found to achieve BP control earlier and were 
found to be less likely to require multiple drugs for BP control than those with Glu65Glu 
genotype (Beitelshees et al., 2007). In another analysis of the INVEST GENE study, 
Verapamil efficacy was investigated for association with the SNPs of endothelial NO 
synthase (eNOS) gene. Nitric Oxide (NO), the product of NOS gene is a critical mediator of 
vascular tone and also has antiplatelet, antiproliferative and antimitogenic effect and eNOS 
activity is important in cardiovascular outcomes and response to treatment. Two commonly 
studied SNPs are NOS3 -786T>C in promoter region, which reduces gene expression 
(Cattaruzza et al., 2004; Iwai et al., 2003; Nakayama et al., 1999) and a nonsynonymous SNP 
(894G>T), which increases its susceptibility to proteolytic cleavage (Tesauro et al., 2000), 
reducing NO bioavailability (Leeson et al., 2002; Persu et al., 2002; Savvidou, Vallance, 
Nicolaides, & Hingorani, 2001). The -786T>C genotype was shown to be significantly 
associated with response to Verapamil; -786C allele carriers showed the greatest reduction 
in SBP/DBP. However, eNOS 894G>T genotypes were not found to significantly affect the 
BP response (M. A. Pacanowski, Zineh, Rhonda M. Cooper-DeHoff, Carl J. Pepine, & Julie 
A. Johnson, 2009). Amlodipine, a dihydropyridine (DHP) class calcium channel blocker is 
another drug routinely prescribed for BP control. In the ALLHAT study conducted in the 
USA and Canada, NPPA T2238C allele was found to be significantly associated with the 
action of this drug. It was seen that TT allele carriers responded better to calcium channel 
blockers (Lynch et al., 2008). However, in order to be useful in clinical settings, these studies 
need to be conducted in wider regions of the world covering more ethnic populations. 
3. Conclusion and future perspectives 
Despite the availability of several effective anti hypertensive drug therapies, optimal control 
of blood pressure remains elusive in a large set of patients. Pharmacogenetics of 
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antihypertensive therapy has the potential to tailor therapy according to patients genetic 
make up as is evidenced by the above Meta analysis. However, prediction of the right drug 
for optimum BP control requires large-scale studies on ethnically diverse populations. Most 
of the studies till date have focused on candidate genes and sample size has ben small. 
Individual groups were only able to detect small effects in their individual population but 
collaborating with other groups conducting GWAS and also focusing on relevant pathways 
will make this more tractable approach and lead to successful clinical translation. 
Replicating these findings across multiple ethnic populations will also be an be an important 
aspect of personalizing treatment on genetic basis and increased international collaboration 
among hypertension pharmacogenomics investigators will be very important to achieve this 
goal. Additionally whole genome mapping of hypertension and blood pressure traits and 
understanding the pharmacogenetics of current drugs will enable the discovery of new drug 
targets in future. 
 
Drug 
Class 
Drug Area Ethnicity 
Sample 
size, N
Genetic variants 
Significant 
difference? 
Reference 
Diuretic Hydrochloro-
thiazide  
USA Non-
Hispanic 
white (50%)
Non-
Hispanic 
Black (50%)
389 LYZ (rs317689) Yes (Turner et al., 
2008) YEATS4 (rs315135) Yes 
USA White 
Caucasian 
(190) 
African 
American 
(197) 
387 GNB3 C825T 
(rs5443) 
Yes (Turner et al., 
2001) 
Chlorthalidone USA  13,860  NPPA T2238C  Yes (Lynch et al., 
2008) 
Hydrochloro-
thiazide 
Taiwan Taiwanese 90 Renin (rs11240688) Yes (C. -C. Huang 
et al., 2011) 
Hydrochloro-
thiazide  
Netherlands Dutch 613 ADD1 Gly460Trp 
(rs4961) 
No (van Wieren-
de Wijer et al., 
2009) 
ǃ 
Blockers 
Dobutamine USA White 163 ADRB1 (Ser49Gly) No (Aquilante et 
al., 2008) ADRB1 
(Arg389Gly)-
rs1801253 
No 
ADRB2 (Arg16Gly) No 
ADRB2 (Gln27Glu) No 
Fluoxetine and 
paroxetine 
USA White 122 ADRB1 
(Arg389Gly)-
rs1801253 
Yes (Turner, 
Bailey, Fridley, 
Chapman, 
Schwartz, 
Chai, Sicotte, 
Kocher, Rodin, 
& Boerwinkle, 
2008b) 
Carvedilol USA Caucasian 110 ADRB2 (Gln27Glu) Yes (Sehrt, 
Meineke, 
Tzvetkov, 
Gültepe, & 
CYP2D6 No 
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Drug 
Class 
Drug Area Ethnicity 
Sample 
size, N
Genetic variants 
Significant 
difference? 
Reference 
Brockmöller, 
2011) 
Atenolol USA African 
Americans 
(69) and 
Caucasian 
White (85) 
151 GRK5-Leu41 
(rs17098707) 
No (Kurnik et al., 
2009) 
Bisoprolol Finland Finnish 233 ADRB1 
(Ser49Gly)(145A>G)-
rs1801252 
No (Suonsyrjä et 
al., 2010) 
ADRB1 
(Arg389Gly)- 
rs1801253 
No 
Amlodipine USA Multi- 
ethnic 
8174  T2238C  Yes (Lynch et al., 
2008) 
Metoprolol China Chinese 61 ADRB1 
(Ser49Gly)(145A>G)-
rs1801252 
Yes (J. Liu et al., 
2003) 
ADRB1 
(Arg389Gly)- 
rs1801253 
Yes 
Atenolol Italy Italians 1112 ADRB1 (Arg389Gly) No (Fabiana 
Filigheddu et 
al., 2010) 
ADRB1 (Ser49Gly)-
(145A>G)-rs1801252 
ADRB2 (Cys19Arg) 
ADRB2 (Gly16Arg) 
ADRB2 (Gln27Glu) 
GNB3 (A3882C) 
GNB3 (G5249A) 
GNB3 (C825T) 
Trandolapril 
and/or 
Atenolol 
USA and 
Puerto Rico
Multiethnic 5,979 ADRB1 Ser49Gly 
(145A>G)-rs1801252 
Yes (Pacanowski et 
al., 2008) 
ADRB1 Arg389Gly 
(1165C>G)- 
rs1801253 
Yes 
ACEI Imidapril or 
benazepril 
China Chinese 517 ACE (I/D) No (Yu, Zhang, & 
Liu, 2003) 
Imidapril or 
benazepril 
China Chinese 501 AGT (M235T) No (H. Yu et al., 
2005) 
Lisinopril USA White 
Caucasians 
(61%) 
7,528 ACE (I/D) No (D. K Arnett et 
al., 2005) 
African 
Americans 
(35%) 
Benazepril China Chinese 1,447 AGT (rs7079 (C/T)) Yes (Su et al., 2007) 
AT1 (multi loci, H2 
& H3) 
Yes 
AT2 (multi loci) No 
Trandolapril USA White 
(35%) 
551 AT1 (A1166C) No (Brunner et al., 
2007) 
Hispanic 
(44%) 
Captopril China Chinese 624 ACE2  (rs2106809) Yes (Fan et al., 
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Drug 
Class 
Drug Area Ethnicity 
Sample 
size, N
Genetic variants 
Significant 
difference? 
Reference 
2007) 
Fosinopril USA White 191 ACE (I/D) No (F. Filigheddu 
et al., 2008) AGT (A-6G) No
AT1 (A1166C) No
Imidapril 
benazepril 
China Chinese 509 AT1 (A1166C) No (H. Yu et al., 
2009) 
Lisinopril USA White non-
Hispanic 
(47%) 
30,076 FGB-455 Yes (Lynch et al., 
2009) 
ACEI Taiwan Taiwanese 623 ACE (rs4343) Yes (Chung et al., 
2010) ABO (rs495828) Yes
ABO (rs8176746) Yes
Perindopril Europe Caucasians 8907 AGTR1 (rs275651) 
Yes 
(Brugts, 
Boersma, & 
Simoons, 2010) 
AGTR1 (rs5182)
BDKRB1 
(rs12050217) 
Enalapril Europe Caucasians 98 AGT (M235T) Yes (Bozec et al., 
2003) 
Telmisartan Europe Caucasians 206 AGT (A-6G) No (Redon, 
Luque-Otero, 
Martell, & 
Chaves, 2004) 
ACE (I/D)
AT1 (A1166C)
AT1 (C573T)
ARB Telmisartan Spain Spanish 206 ACE (I/D) No (Redon, 
Luque-Otero, 
Martell, & 
Chaves, 2004) 
AGT (A-6G) No
AT1 (A1166C) No
AT1 (C573T) No
Valsartan Japan Japanese 231 ACE (I/D) No (Konoshita, 
2011) AGT (M235T) No
AT1 (A1166C) No
AT2 (C3123A) No
REN (C-5312T) Yes
Losartan Scandinavia White 
(92%) 
1,774 ACE (I/D) No (Nordestgaard 
et al., 2010) 
 
 
AGT (M235T) No
AT1 (A1166C) No
Calcium 
channel 
blockers 
Verapamil SR USA Hispanics, 
White 
Caucasians 
and Afro 
Americans 
5979 KCNMB1 
(Glu65Lys) 
No (Beitelshees et 
al., 2007) 
KCNMB1 
(Val110Leu) 
No
Verapamil SR USA Hispanics, 
White 
Caucasians 
and Afro 
Americans 
1025 NOS3 (-
786T>C)(rs2070744) 
Yes (M. 
Pacanowski et 
al., 2008) NOS3 Glu298>Asp
(rs1799983) 
No
Amlodipine USA and 
Canada 
Multi-
ethnic 
8174 NPPA (T2238C) Yes (Lynch et al., 
2008) 
Table 1.  
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